Oramed Pharmaceuticals (NASDAQ:ORMP) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.09), Fidelity Earnings reports. Oramed Pharmaceuticals had a negative return on equity of 28.75% and a negative net margin of 230.07%.
NASDAQ:ORMP traded down $0.10 during mid-day trading on Friday, reaching $4.36. The company’s stock had a trading volume of 7,773 shares, compared to its average volume of 164,833. The stock has a fifty day moving average of $4.28 and a 200-day moving average of $3.45. Oramed Pharmaceuticals has a 1 year low of $2.40 and a 1 year high of $5.71. The firm has a market capitalization of $103.23 million, a PE ratio of -13.51 and a beta of 1.58.
Separately, Alliance Global Partners initiated coverage on shares of Oramed Pharmaceuticals in a research report on Thursday, December 3rd. They set a “buy” rating and a $11.00 price objective on the stock.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
Recommended Story: What Does Beta Mean In Stock Selection?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.